Federal Circuit Overturns Ineligibility Ruling for Gene Therapy Intellectual Property

By Editorial Team

The Federal Circuit recently reversed a ruling that deemed Regenxbio and the University of Pennsylvania's gene therapy patent ineligible. The court found that the process of combining genes from different organisms results in a molecule that is significantly different from anything found in nature, thereby making the therapy patent eligible.

Regenxbio and the University of Pennsylvania were facing a challenge to their gene therapy patent, which involved splicing together genes from various organisms. The challenge questioned the eligibility of the patent, arguing that the process did not create anything markedly different from what occurs naturally.

However, the Federal Circuit disagreed with this assessment and determined that the molecule resulting from the combination of genes was indeed distinct from naturally occurring substances. This decision ultimately upheld the patent eligibility of the gene therapy developed by Regenxbio and the University of Pennsylvania.

The ruling by the Federal Circuit is significant as it clarifies the eligibility of gene therapy patents that involve the combination of genetic material from different sources. This decision provides important guidance for future cases involving similar intellectual property challenges in the field of gene therapy.

For more information on this case and its implications for gene therapy intellectual property, please refer to the attached opinion document.